MSI、PD—L1及IL—6在结直肠腺癌中的表达及意义(4)
[5] Korehisa S,Oki E,Iimori M,et al.Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability[J].Int J Cancer,2018,142(4):822-832.
[6] Inoue Y,Miki C,Watanabe H,et al.Genomic instability and tissue expression of angiogenic growth factors in sporadic colorectal cancer[J].Surgery,2006,139(3):305-311.
[7] Hancock J F.Ras proteins:different signals from different locations[J].Nat Rev Mol Cell Biol,2003,4:373-384.
[8] Lorenc Z,Waniczek D,Lorenc-Podgórska K,et al.Profile of Expression of Genes Encoding Matrix Metallopeptidase 9(MMP9),Matrix Metallopeptidase 28(MMP28) and TIMP Metallopeptidase Inhibitor 1(TIMP1) in Colorectal Cancer:Assessment of the Role in Diagnosis and Prognostication[J].Med Sci Monit,2017,23:1305-1311.
[9] Fletcher R,Wang Y J,Schoen R E,et al.Colorectal cancer prevention:Immune modulation taking the stage[J].Biochim Biophys Acta,2018,1869(2):138-148.
[10] Pardoll D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
[11] O’Neil B H,Wallmark J M,Lorente D,et al.Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma[J].PLoS One,2017,12(12):e0189848.
[12] Topalian S L,Sznol M,Mcdermott D F,et al.Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab[J].Journal of Clinical Oncology,2014,32(10):1020-1030.
[13] Ribas A,Shin D S,Zaretsky J,et al.PD-1 Blockade Expands Intratumoral Memory T Cells[J].Cancer Immunology Research,2016,4(3):194-203.
[14] Ohno Y,Toyoshima Y,Yurino H,et al.Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy[J].Cancer Sci,2017,108(10):1959-1966.
[15] Xiao Y,Freeman G J.The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy[J].Cancer Discov,2015,5(1):16-18.
(收稿日期:2018-04-03) (本文編辑:张爽), 百拇医药(王超 郑绘霞)
[6] Inoue Y,Miki C,Watanabe H,et al.Genomic instability and tissue expression of angiogenic growth factors in sporadic colorectal cancer[J].Surgery,2006,139(3):305-311.
[7] Hancock J F.Ras proteins:different signals from different locations[J].Nat Rev Mol Cell Biol,2003,4:373-384.
[8] Lorenc Z,Waniczek D,Lorenc-Podgórska K,et al.Profile of Expression of Genes Encoding Matrix Metallopeptidase 9(MMP9),Matrix Metallopeptidase 28(MMP28) and TIMP Metallopeptidase Inhibitor 1(TIMP1) in Colorectal Cancer:Assessment of the Role in Diagnosis and Prognostication[J].Med Sci Monit,2017,23:1305-1311.
[9] Fletcher R,Wang Y J,Schoen R E,et al.Colorectal cancer prevention:Immune modulation taking the stage[J].Biochim Biophys Acta,2018,1869(2):138-148.
[10] Pardoll D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
[11] O’Neil B H,Wallmark J M,Lorente D,et al.Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma[J].PLoS One,2017,12(12):e0189848.
[12] Topalian S L,Sznol M,Mcdermott D F,et al.Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab[J].Journal of Clinical Oncology,2014,32(10):1020-1030.
[13] Ribas A,Shin D S,Zaretsky J,et al.PD-1 Blockade Expands Intratumoral Memory T Cells[J].Cancer Immunology Research,2016,4(3):194-203.
[14] Ohno Y,Toyoshima Y,Yurino H,et al.Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy[J].Cancer Sci,2017,108(10):1959-1966.
[15] Xiao Y,Freeman G J.The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy[J].Cancer Discov,2015,5(1):16-18.
(收稿日期:2018-04-03) (本文編辑:张爽), 百拇医药(王超 郑绘霞)